Momenta Pharmaceuticals (MNTA) 15.46 $MNTA 21.0% Return

New Post Public Reply Private Reply Replies (0) Message Board

Mar 21, 2015 at 9:12 PM

Momenta Pharmaceuticals (MNTA) 15.46 $MNTA

21.0% Return Seen to Date on SmarTrend Momenta Pharmaceuticals Call (MNTA)
Comtex SmarTrend(R) - Thu Mar 19, 11:35AM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on February 18th, 2015 at $12.52. In approximately 4 weeks, Momenta Pharmaceuticals has returned 20.97% as of today's recent price of $15.14.
MNTA: 15.46 (-0.01)

Shares of MNTA Up 17.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Mar 12, 11:28AM CDT
SmarTrend identified an Uptrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on February 18th, 2015 at $12.52. In approximately 3 weeks, Momenta Pharmaceuticals has returned 17.30% as of today's recent price of $14.68.
MNTA: 15.46 (-0.01)

Momenta Pharmaceuticals Announces Publication Revealing Development of a Novel Process to Generate High-Quality Hyper-sialylated IVIg Drug Candidate in PNAS
GlobeNewswire - Mon Mar 02, 2:34PM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that results from preclinical studies on its hyper-sialylated IVIg (hsIVIg) program were published in this week's Early Edition of Proceedings of the National Academy of Sciences (PNAS). The article summarizes Momenta's progress in creating a hsIVIg drug candidate with the potential for more consistent and enhanced anti-inflammatory activity compared to the current IVIg therapy used to treat inflammatory and autoimmune diseases.
MNTA: 15.46 (-0.01)

Insider Trading Alert - IBM, EMC And MNTA Traded By Insiders
at The Street - Thu Feb 26, 9:15AM CST
Stocks with insider trader activity include IBM, EMC and MNTA
IBM: 162.88 (+3.07), EMC: 26.70 (+0.49), MNTA: 15.46 (-0.01)

Why Momenta Pharmaceuticals, Inc. Jumped Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Thu Feb 19, 3:57PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Momenta Pharmaceuticals shares surged...
BAX: 68.18 (+0.20), TEVA: 62.10 (+0.55), ABBV: 60.40 (-0.79), BMY: 67.76 (-0.56), MNTA: 15.46 (-0.01), NVS: 101.68 (+1.81)

Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Feb 18, 7:13PM CST

MNTA: 15.46 (-0.01)

Momenta (MNTA) Posts Wider-than-Expected Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 18, 8:27AM CST
Momenta Pharmaceuticals Inc.'s (MNTA) reported fourth-quarter 2014 loss of 31 cents per share, wider than the Zacks Consensus Estimate of a loss of 16 cents.
BAX: 68.18 (+0.20), TEVA: 62.10 (+0.55), MNTA: 15.46 (-0.01), NVS: 101.68 (+1.81)

Momenta Pharmaceuticals to Webcast Presentation at Cowen and Company's 35th Annual Health Care Conference
GlobeNewswire - Wed Feb 18, 8:09AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at Cowen and Company's 35th Annual Health Care Conference will be webcast on Tuesday, March 3 at 10:40 a.m. ET.
MNTA: 15.46 (-0.01)

Waiting for the Momenta to Regain
Brian Orelli, The Motley Fool - Motley Fool - Tue Feb 17, 2:02PM CST
There's potential for a lot to happen for Momenta Pharmaceuticals this year, but at this point the biotech is waiting on quite a few outside forces: potential partner(s), the FDA, and the court system. While that would normally make for a rather...
BAX: 68.18 (+0.20), TEVA: 62.10 (+0.55), ABBV: 60.40 (-0.79), BMY: 67.76 (-0.56), SNY: 50.64 (+1.17), MNTA: 15.46 (-0.01), NVS: 101.68 (+1.81)

Momenta Pharmaceuticals (MNTA) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Feb 17, 8:55AM CST

MNTA: 15.46 (-0.01)

Be on Top of the Latest Happenings: Special Research on La Jolla, Lpath, Macrocure, Momenta, and NanoString
PR Newswire - Tue Feb 17, 8:05AM CST
Editor Note: For more information about this release, please scroll to bottom.
NSTG: 11.48 (-0.05), LJPC: 22.38 (-0.71), MCUR: 9.63 (-0.06), MNTA: 15.46 (-0.01), LPTN: 3.46 (-0.21)

Momenta Pharma ups revenues 66% in Q4
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 7:31AM CST

MNTA: 15.46 (-0.01)

Momenta reports 4Q loss
Automated Insights - Tue Feb 17, 7:22AM CST
CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Tuesday reported a loss of $16 million in its fourth quarter.
MNTA: 15.46 (-0.01)

Momenta Pharmaceuticals misses by $0.05, misses on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 17, 7:02AM CST

MNTA: 15.46 (-0.01)

Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial Results
GlobeNewswire - Tue Feb 17, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2014.
MNTA: 15.46 (-0.01)

Notable earnings before Tuesday’s open
Seeking Alpha - at Seeking Alpha - Mon Feb 16, 4:30PM CST

MDT: 78.02 (+0.36), GPC: 95.93 (+0.40), WLT: 0.57 (-0.04), PES: 4.88 (+0.22), TGH: 30.63 (+1.06), CRY: 10.12 (-0.25), LECO: 65.06 (-1.54), MGM: 22.62 (-0.23), USAC: 20.45 (+0.75), MNTA: 15.46 (-0.01), WM: 54.55 (-0.18), TTS: 11.33 (+0.52), ACC: 43.76 (+1.50), QSR: 38.97 (-0.87), VDSI: 23.13 (-1.57), GT: 25.66 (+0.48), WWW: 31.50 (+0.40), WRI: 37.19 (+0.81), ALE: 53.47 (+0.45), AGIO: 107.97 (-2.99), NHI: 72.61 (+1.74), VNR: 14.75 (+0.73)

3 Blockbuster Drugs That May Be Obsolete in 5 Years
Motley Fool Staff - Motley Fool - Sat Feb 07, 12:28PM CST
Blockbuster status is the Holy Grail for drug developers, but patent expirations mean these billion-dollar drugs have a limited shelf life. These three drugs, for example, have been among the planet's best-sellers, but over the course of the next...
JNJ: 102.40 (+0.71), BIIB: 475.98 (+42.33), ESRX: 85.38 (+1.43), PTLA: 41.00 (-0.40), PFE: 34.25 (+0.10), AZN: 72.70 (+1.80), TEVA: 62.10 (+0.55), GSK: 48.81 (+0.60), BMY: 67.76 (-0.56), MNTA: 15.46 (-0.01), NVS: 101.68 (+1.81)

Momenta Pharmaceuticals Is A Low-Risk, High-Reward Long-Term Gamble
Clinically Sound Investor - at Seeking Alpha - Sat Feb 07, 6:25AM CST

MNTA: 15.46 (-0.01)

Momenta Pharma reports February 17
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 8:19AM CST

MNTA: 15.46 (-0.01)

Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Feb 03, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the fourth quarter and year ended December 31, 2014 before the U.S. financial markets open on Tuesday, February 17, 2015.
MNTA: 15.46 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NOTHING NINE's Global Ambitions: Paris Show's Impact

Paris: Stage or Launchpad? You’d think walking that catwalk in Paris is the holy grail—fashion's own illustrious red carpet. But when you're Chloe, founder of NOTHING NINE, the real hustle kicks off once the lights dim. On 29th September 2026, this designer brand strutted its stuff at one of the grandest venues, Les Invalides, part of the prestigious Paris Fashion...

Temu Partners with Recyclia to Drive EPR Compliance Boost

Temu and Recyclia: Building a Sustainable Marketplace Get this: Temu, the e-commerce giant you've heard trumpeting about affordable goods like some digital bazaar, is diving deeper into sustainability waters with a partner that knows a thing or two about waste. This time, they've linked up with Recyclia over in Spain. The duo's focus? Helping marketplace sellers meet the...

Medline's Decade-Long WRAP Partnership: More Than Labels

A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...

SUNON's Approach to AI-Driven Workspaces Debuted at ORGATEC

SUNON's Unique Spin on Future Workspaces The world of workplace solutions is buzzing with ideas on how to blend smart tech with soulful spaces. This year, SUNON is hitting ORGATEC 2026 in Cologne with a bold approach that stitches AI, nature, and circular design right into the fabric of office life. They’re not just setting up shop; they’re promising a peek into a...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

CStone's CS2009: A Leap in Cancer Treatment Validated

CStone's Game-Changer: CS2009 in the Spotlight CStone Pharmaceuticals just pulled a rabbit out of a hat at the ESMO 2026 Congress, showcasing the clinical might of their CS2009. This ain't just another hype train, folks. We're talking about a trispecific antibody targeting PD-1, VEGF, and CTLA-4. With data rolled out from over 300 patients, this compound promises a...

Air Sealing First: Boosting Home Comfort & Efficiency

Everyone wants a cozy, energy-efficient home, right? Well, the first step to achieving that might just surprise you. Forget about shoving more insulation into the walls for a second; air sealing should be your starting line. That's the drum Insulation Expert Mike Mancuso is beating, and he's got a point worth considering before you touch another insulation panel. Cracking...

Artprice Champions Creative Freedom with AI in 2026

AI and the Creative Reawakening As the autumn of 2026 rolls in, publishing circles are buzzing over artificial intelligence's role in artistry. Weekly updates hailing rejection, tolerance, or adaptation of AI in writing stir the pot. Yet, Artprice by Artmarket stands out by anchoring creative freedom and responsibility in the spotlight. Grounded on an initiative launched...

Sirha Lyon® 2027: A New Chapter in Foodservice

A Bold Step Forward There's a hearty aroma wafting from Lyon this January, and it's not just from the local gastronomy. Sirha Lyon® is queuing up for its 23rd edition, promising to turn the Foodservice and Hospitality sectors on their heads. Nearly 150,000 square meters of exhibition space packed to the rafters with over 4,300 exhibitors—this ain't your average trade...

OncoHost's Research Links TKI Sensitivity to Biology

Cracking the Code on TKI Sensitivity When it comes to medicine, sometimes the trickiest part is knowing which button to push—especially in the high-stakes world of metastatic renal cell carcinoma (mRCC). OncoHost just dropped a bombshell at the ESMO 2026 Congress about their new plasma proteomics model that lets us peer into what makes some patients click with Tyrosine...